Clinical trial

A Single Centre, Controlled, Investigation to Evaluate the Performance of the Hyperspectral Camera for Retinal Non-invasive Examination Through the Observation of Retinal Oxygenation

Name
MANTIS_2022_08_Oxygenation_S
Description
An explorative study of the Mantis Photonics hyperspectral camera for retinal imaging and estimation of retinal oxygenation. Primary objective: To evaluate the performance of the hyperspectral camera for non-invasive retinal examination in order to improve the diagnosis of diseases affecting the retina or central nervous system. Secondary objective: To investigate the possibilities of the use of a hyperspectral camera for non-invasive retinal examination.
Trial arms
Trial start
2022-10-01
Estimated PCD
2023-11-01
Trial end
2023-12-01
Treatment
Hyperspectral retinal image
Hyperspectral image of both eyes
Arms:
Camera test group
Other names:
hyperspectral retinoscopy
Mydriacyl Ophthalmic Product
Mydriatic drops before retinoscopy
Arms:
Camera test group
Size
120
Primary endpoint
Performance evaluation - Retinal Oxygenation
During the procedure (retinoscopy with hyperspectral camera).
Eligibility criteria
For inclusion in the investigation, the patient-subjects must fulfill all of the below criteria prior to enrollment: 1. Age \> 18 years. 2. Ophthalmological disease, disorder, illness or problem involving the retina 3. Provision of informed consent i.e., subject must be able to understand and sign the patient information and consent form. For inclusion in the investigation, the healthy subjects must fulfill all of the below criteria prior to enrollment: 1. Age \>18 years. 2. Without known eye disease. 3. Provision of informed consent i.e., subject must be able to understand and sign the patient information and consent form. Patients-subjects who meet any of the below criteria will be excluded from the investigation: 1. Patients with narrow angle glaucoma 2. Inclusion in other ongoing investigations at present that would preclude the subject from participating in this investigation as judged by the Principal Investigator. Healthy subjects who meet any of the below criteria will be excluded from the investigation: 1. Presence of eye disease, eye trauma, diabetes or pregnancy. 3. Inclusion in other ongoing investigations at present that would preclude the subject from participating in this investigation as judged by the Principal Investigator.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'Alle participants, both healthy subjects and patients, receive the same intervention: hyperspectral image with Mantis Photonics camera', 'primaryPurpose': 'DIAGNOSTIC', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 120, 'type': 'ESTIMATED'}}
Updated at
2022-10-21

1 organization

1 product

4 indications

Organization
Mantis Photonics
Product
Mydriacyl
Indication
Glaucoma